Actively Recruiting
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer
Led by Janssen Research & Development, LLC · Updated on 2026-06-05
520
Participants Needed
110
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the anti-tumor activity and safety of amivantamab given as a subcutaneous co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) in participants with advanced or metastatic non-small cell lung cancer (NSCLC), including those with specific EGFR mutations. This Phase 2, open-label study includes multiple cohorts with different treatment histories and EGFR mutation types to better understand how amivantamab works in combination with other therapies and to assess its safety profile. Participants receive amivantamab subcutaneously at varying doses based on body weight and specific treatment cohorts. Some cohorts combine amivantamab with oral lazertinib or intravenous chemotherapy drugs such as carboplatin and pemetrexed, administered on different schedules ranging from every two to three weeks in 21- or 28-day cycles. Additional treatments like prophylactic anticoagulation may also be given in certain cohorts. Participants may have the option to enter a long-term extension phase to continue receiving study treatments. During the study, participants undergo regular evaluations including tumor assessments based on RECIST criteria and safety monitoring through adverse event tracking and laboratory tests. Researchers will measure objective response rates and other outcomes up to 1 year and 6 months, and for some cohorts, safety will be monitored for up to nearly 5 years. Participants' quality of life and treatment satisfaction are also assessed. The total duration of participation varies according to cohort and treatment response, with follow-up continuing after treatment completion.
CONDITIONS
Brief Title
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer (NSCLC) not suitable for curative therapy
- Specific EGFR mutations required by cohort: exon 19 deletion, exon 21 L858R, or exon 20 insertion mutations
- Some cohorts require no prior systemic therapy for advanced NSCLC
- Some cohorts require progression after treatment with osimertinib or amivantamab plus lazertinib
- At least one measurable tumor lesion per RECIST 1.1 criteria (except Cohort 4)
- ECOG performance status of 0 or 1
- Adequate organ function (renal, hepatic, hematological, coagulation, cardiac)
- For Cohort 6, eligibility and agreement to use prophylactic anticoagulation during first 4 months of treatment
- Agreement not to donate or freeze eggs during the study and for 6 months after last dose
You will not qualify if you...
- History of interstitial lung disease (ILD) or radiation pneumonitis
- Hypersensitivity to any ingredients of study treatments
- Receipt of live or live attenuated vaccine within 3 months before starting treatment (except for seasonal flu and non-live COVID-19 vaccines)
- Current use of strong CYP3A4/5 inducers unable to be stopped before treatment
- Active infectious liver disease
- Significant cardiovascular disease including recent deep vein thrombosis, pulmonary embolism, myocardial infarction, stroke, uncontrolled hypertension, heart failure, myocarditis, or low left ventricular ejection fraction
- Symptomatic brain metastases; stable treated brain metastases allowed with low or no corticosteroids
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 1 year and 6 months
Participants receive subcutaneous injections of amivantamab and other study drugs as per their cohort assignment. Treatment involves cycles of drug administration every 2 to 4 weeks, combined with oral or intravenous therapies depending on the cohort. Chemotherapy, oral anticoagulants, or combination regimens may be included based on the treatment group.
Weekly or biweekly visits during initial cycles, then every 2 to 4 weeks according to treatment schedule
Duration - Up to approximately 4 years and 9 months
Participants who continue to benefit from the study treatment may enter the long-term extension phase to receive ongoing access to study drugs.
Visits as per investigator discretion during extended treatment
Trial Site Locations
Total: 110 locations
1
University of California at San Diego
La Jolla, California, United States, 92093
Actively Recruiting
2
University of California Irvine
Orange, California, United States, 92868
Actively Recruiting
3
Stanford Cancer Institute
Stanford, California, United States, 94305
Actively Recruiting
4
Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
Washington D.C., District of Columbia, United States, 20016
Actively Recruiting
5
Baptist Lynn Cancer Institute
Boca Raton, Florida, United States, 33486
Completed
6
Mount Sinai Medical Center
Miami Beach, Florida, United States, 33140
Actively Recruiting
7
AdventHealth
Orlando, Florida, United States, 32804
Actively Recruiting
8
H. Lee Moffitt Cancer & Research Institute
Tampa, Florida, United States, 33612
Completed
9
University of Kansas Cancer Center
Westwood, Kansas, United States, 66205
Actively Recruiting
10
Sidney Kimmel Cancer Center - Bayview Campus
Baltimore, Maryland, United States, 21224
Actively Recruiting
11
Boston Medical Center
Boston, Massachusetts, United States, 02118
Actively Recruiting
12
Washington University School Of Medicine
St Louis, Missouri, United States, 63110
Actively Recruiting
13
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
Actively Recruiting
14
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901
Actively Recruiting
15
Hematology-Oncology Associates of CNY
East Syracuse, New York, United States, 13057
Completed
16
Novant Health 1
Charlotte, North Carolina, United States, 28204
Completed
17
Novant Health
Winston-Salem, North Carolina, United States, 27106
Completed
18
Cleveland Clinic 1
Cleveland, Ohio, United States, 44111
Completed
19
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Completed
20
Cleveland Clinic 2
Mayfield Heights, Ohio, United States, 44124
Completed
21
Cleveland Clinic 3
Warrensville Heights, Ohio, United States, 44122
Completed
22
The Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Completed
23
Virginia Cancer Specialists
Fairfax, Virginia, United States, 22031
Actively Recruiting
24
Providence Regional Cancer Partnership
Everett, Washington, United States, 98201
Completed
25
Virginia Mason Medical Center
Seattle, Washington, United States, 98101
Completed
26
Swedish Cancer Institute
Seattle, Washington, United States, 98104
Actively Recruiting
27
Fundacao Pio XII
Barretos, Brazil, 14784-400
Actively Recruiting
28
PERSONAL Oncologia de Precisao e Personalizada
Belo Horizonte, Brazil, 30130 090
Actively Recruiting
29
Instituto do Cancer de Londrina Hospital do Cancer de Londrina
Londrina, Brazil, 86015
Actively Recruiting
30
Associacao Hospitalar Moinhos de Vento
Porto Alegre, Brazil, 90035-001
Actively Recruiting
31
Instituto D Or de Pesquisa e Ensino IDOR
Rio de Janeiro, Brazil, 22281 100
Actively Recruiting
32
Instituto D Or de Pesquisa e Ensino IDOR 1
Salvador, Brazil, 41253-190
Actively Recruiting
33
Hospital Alemao Oswaldo Cruz
São Paulo, Brazil, 01327 001
Actively Recruiting
34
Impar Servicos Hospitalares SA Hospital Nove de Julho
São Paulo, Brazil, 01409-001
Completed
35
Fundacao Antonio Prudente A C Camargo Cancer Center
São Paulo, Brazil, 01509 900
Actively Recruiting
36
Affiliated Hospital of Hebei University
Baoding, China, 071051
Completed
37
Jilin cancer hospital
Changchun, China, 130000
Actively Recruiting
38
Sichuan Cancer Hospital
Chengdu, China, 610041
Actively Recruiting
39
West China Hospital Sichuan University
Chengdu, China, 610047
Actively Recruiting
40
The First Affiliated Hospital of PLA Army Medical University
Chongqing, China, 400038
Actively Recruiting
41
The First Affiliated Hospital Sun Yat sen University
Guangzhou, China, 510060
Actively Recruiting
42
The First Affiliated Hospital Zhejiang University College of Medicine
Hangzhou, China, 310003
Actively Recruiting
43
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
Hangzhou, China, 310016
Actively Recruiting
44
Harbin medical university cancer hospital
Harbin, China, 150000
Actively Recruiting
45
Huizhou Municipal Central Hospital
Huizhou, China, 516001
Actively Recruiting
46
Liuzhou people's Hospital
Liuzhou, China, 545006
Completed
47
Fudan University Shanghai Cancer Center
Shanghai, China, 200032
Actively Recruiting
48
Tianjin Medical University General Hospital
Tianjin, China, 300052
Actively Recruiting
49
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, China, 325000
Actively Recruiting
50
Union Hospital Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China, 430022
Actively Recruiting
51
Hospital of Jiangnan University
Wuxi, China, 214122
Completed
52
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, China, 710061
Actively Recruiting
53
Yantai Yuhuangding Hospital
Yantai, China, 264000
Completed
54
Centre Francois Baclesse
Caen, France, 14076
Actively Recruiting
55
Centre Georges-François Leclerc
Dijon, France, 21079
Completed
56
Institut de Cancérologie du Gard
Nîmes, France, 30029
Actively Recruiting
57
Institut Curie
Paris, France, 75248
Actively Recruiting
58
Institut de cancerologie de l'ouest
Saint-Herblain, France, 44805
Actively Recruiting
59
Gustave Roussy
Villejuif, France, 94800
Actively Recruiting
60
Evangelische Lungenklinik Berlin
Berlin, Germany, 13125
Completed
61
Universitaetsklinikum Koeln
Cologne, Germany, 50937
Actively Recruiting
62
LungenClinic Grosshansdorf GmbH
Grosshandorf, Germany, 22927
Actively Recruiting
63
Lungenfachklinik Immenhausen
Immenhausen, Germany, 34376
Actively Recruiting
64
Klinikum Würzburg Mitte gGmbH Standort Missioklinik
Würzburg, Germany, 97074
Actively Recruiting
65
Rambam Medical Center
Haifa, Israel, 3109601
Actively Recruiting
66
Shaare Zedek Medical Center
Jerusalem, Israel, 9103102
Actively Recruiting
67
Meir Medical Center
Kfar Saba, Israel, 44281
Completed
68
Rabin Medical Center
Petah Tikva, Israel, 4941492
Actively Recruiting
69
Sheba Medical Center
Ramat Gan, Israel, 52621
Actively Recruiting
70
Policlinico Hospital San Martino- IRCCS for Oncology
Genova, Italy, 16132
Actively Recruiting
71
Ospedale San Raffaele
Milan, Italy, 20132
Actively Recruiting
72
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy, 20162
Actively Recruiting
73
Azienda Ospedaliera San Gerardo
Monza, Italy, 20090
Actively Recruiting
74
Azienda Ospedaliera Specialistica dei Colli
Naples, Italy, 80131
Actively Recruiting
75
National Hospital Organization Himeji Medical Center
Himeji, Japan, 670-8520
Active, Not Recruiting
76
Saiseikai Matsusaka Municipal Hospital
Matsusaka, Japan, 515 8544
Active, Not Recruiting
77
Niigata Cancer Center Hospital
Niigata, Japan, 951-8566
Active, Not Recruiting
78
Shizuoka Cancer Center
Shizuoka, Japan, 411 8777
Active, Not Recruiting
79
The Cancer Institute Hospital of JFCR
Tokyo, Japan, 135 8550
Active, Not Recruiting
80
Wakayama Medical University Hospital
Wakayama, Japan, 641 8510
Active, Not Recruiting
81
University Malaya Medical Centre
Kuala Lumpur, Malaysia, 59100
Actively Recruiting
82
Hospital Tengku Ampuan Afzan
Kuantan, Malaysia, 25100
Actively Recruiting
83
Hospital Umum Sarawak
Kuching, Malaysia, 93586
Actively Recruiting
84
Beacon Hospital Sdn Bhd
Petaling Jaya, Malaysia, 46050
Actively Recruiting
85
National Cancer Center
Goyang-si, South Korea, 10408
Actively Recruiting
86
Seoul National University Bundang Hospital
Seongnam-si, South Korea, 13620
Actively Recruiting
87
Seoul National University Hospital
Seoul, South Korea, 03080
Actively Recruiting
88
Severance Hospital Yonsei University Health System
Seoul, South Korea, 03722
Actively Recruiting
89
Asan Medical Center
Seoul, South Korea, 05505
Completed
90
Hosp Univ A Coruna
A Coruña, Spain, 15006
Actively Recruiting
91
General University Hospital of Alicantet
Alicante, Spain, 03010
Actively Recruiting
92
Hosp. Del Mar
Barcelona, Spain, 08003
Actively Recruiting
93
Hosp. de La Santa Creu I Sant Pau
Barcelona, Spain, 08025
Actively Recruiting
94
Hosp Univ Vall D Hebron
Barcelona, Spain, 08035
Actively Recruiting
95
Inst. Cat. Doncologia-H Duran I Reynals
Barcelona, Spain, 8908
Actively Recruiting
96
Hosp. Gral. Univ. Gregorio Maranon
Madrid, Spain, 28007
Actively Recruiting
97
Hosp. Univ. Ramon Y Cajal
Madrid, Spain, 28034
Actively Recruiting
98
Hosp. Univ. 12 de Octubre
Madrid, Spain, 28041
Actively Recruiting
99
Hosp. Univ. La Paz
Madrid, Spain, 28046
Actively Recruiting
100
Hosp Regional Univ de Malaga
Málaga, Spain, 29010
Actively Recruiting
101
Hosp. Virgen Macarena
Seville, Spain, 41009
Actively Recruiting
102
Hosp. Clinico Univ. de Valencia
Valencia, Spain, 46010
Actively Recruiting
103
Hosp. Gral. Univ. Valencia
Valencia, Spain, 46014
Actively Recruiting
104
Cheltenham General Hospital
Cheltenham, United Kingdom, GL53 7AN
Completed
105
Torbay Hospital-Devon
Devon, United Kingdom, TQ2 7AA
Actively Recruiting
106
Edinburgh Cancer Centre Western General
Edinburgh, United Kingdom, EH4 2XU
Actively Recruiting
107
Leicester Royal Infirmary
Leicester, United Kingdom, LE1 5WW
Actively Recruiting
108
University College London Hospitals
London, United Kingdom, NW1 2PG
Actively Recruiting
109
Nottingham City Hospital
Nottingham, United Kingdom, NG5 1PB
Actively Recruiting
110
Queen Alexandra Hospital
Portsmouth, United Kingdom, PO6 3LY
Actively Recruiting
Research Team
S
Study Contact
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
8
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here